BioSight
Companies
Lyell Immunopharma, Inc. logo

LYEL

NASDAQSOUTH SAN FRANCISCO, CA
Lyell Immunopharma, Inc.

Lyell Immunopharma develops cell therapies, including CAR-T treatments, for cancer and other diseases. The firm's lead candidates are rondecabtagene autoleucel (ronde-cel) and LYL273, which are in clinical development stages. Lyell is pursuing regulatory designations such as Regenerative Medicine Advanced Therapy and Orphan Drug status for its pipeline programs.

Price history not yet available for LYEL.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar